Back

Distilling the clinical evidence behind the WCD - What have clinical trials and registries told us?

25 May 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Who should receive the wearable cardioverter defibrillator? Evidence and risk stratification for prevention of sudden cardiac death Treatment HFA Premium Access Heart Failure 2019

About the speaker

Photo
Professor Christian Veltmann

Heart Center Bremen, Bremen (Germany)

4 More presentations in this session

Presentation thumbnail
Introduction - Who should receive the wearable cardioverter defibrillator? Evidence and risk stratification for prevention of sudden cardiac death
Professor L. Kober (Copenhagen, DK)
Video
Presentation thumbnail
Taking your time in the treatment of newly diagnosed heart failure patients.
Doctor J. Erath (Frankfurt, DE)
Slides Video
Presentation thumbnail
The impact of the WCD for patients who choose to wear it.
Professor A. Flammer (Zurich, CH)
Slides Video
Presentation thumbnail
Panel discussion and summary - Who should receive the wearable cardioverter defibrillator? Evidence and risk stratification for prevention of sudden cardiac death.
Professor C. Leclercq (Rennes, FR)
Video

Access the full session

Session thumbnail
Who should receive the wearable cardioverter defibrillator? Evidence and risk stratification for prevention of sudden cardiac death

The Event

Event poster

Heart Failure 2019

25 May - 28 May 2019
You may be interested in
thumbnail
Congress Session
Ventricular storm (2)
thumbnail
Congress Presentation
When to consider device therapy in HFrEF - discussion
thumbnail
Congress Presentation
Case 2 - implantable cardioverter defibrillator, catheter ablation, or both for secondary prevention?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources